Bayer/Onyx’ Nexavar Approved For Kidney Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.